Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRN on ODS

This article was originally published in The Tan Sheet

Executive Summary

NIH's Office of Dietary Supplements "should overtly and in a transparent manner offer its reports as advice," CRN VP-Scientific & International Affairs John Hathcock, PhD, said in materials presented during a meeting on ODS' five-year Strategic Plan May 20 in Bethesda, Md. Hathcock noted that some needs are not being met to expand outreach to the public, scientists and healthcare providers. The CRN VP also recommended that the HHS secretary and agency heads at CDC and NIH "should overtly seek and consider the advice of ODS on [dietary supplement] issues"...

You may also be interested in...



Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer

Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.

Shuren Gives Peek Behind Curtain With 3 Lessons FDA’s Device Center Learned During Pandemic

CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel